Sun Pharma settles litigation for drug

As per IMS, Gleevec had annual sales of approximately $2 billion in the US


Sun pharma executes settlement agreement with Novartis Pharma Corporation

Sun Pharmaceutical Industries Ltd. announced that one of its subsidiaries has executed a settlement agreement with Novartis Pharmaceuticals Corporation stipulating a dismissal of the lawsuits filed in the United States against the Company regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gleevec, Imatinib Mesylate tablets. These tablets are indicated for the treatment of chronic myeloid leukemia.

Under the terms of the settlement agreement, Sun Pharma's subsidiary may launch its version of generic Gleevec in the United States on February 1, 2016. The other terms of the agreement are confidential. The agreement is subject to customary regulatory approvals.

Sun Pharma's subsidiary holds a tentative approval from the US FDA for its ANDA for a generic version of Gleevec.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email